



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 47/60 (2017.01) A61K 47/64 (2017.01)
A61K 39/00 (2006.01) A61K 39/395 (2006.01)
C12N 15/63 (2006.01)

6514867 Tel Aviv (IL). **SAPIR, Yair**; 2018400 Manof (IL). **SHULMAN, Avidor**; 7 Shaked Street, 2017500 Rakefet (IL). **ZELTSBURG, Lilach Chen**; Shaked 10/34, Nahariya, 2235813 (IL). **LEWKOWICZ, Ayala**; Kibbutz Kfar Szold, 1223000 (IL).

(21) International Application Number:

PCT/IL2021/050271

(74) Agent: **KESTEN, Dov** et al.; GEYRA KESTEN, 100 Hashmonaim Street, P.O. Box 52630, 6713317 Tel Aviv (IL).

(22) International Filing Date:

11 March 2021 (11.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/988,503 12 March 2020 (12.03.2020) US

(71) Applicant: **BIOND BIOLOGICS LTD.** [IL/IL]; Yarok Street, P.O. Box 4, 2017400 Misgav Industrial Park (IL).


(72) Inventors: **HAKIM, Motti**; P.O. Box 45, Kibbutz Gazit, 1934000 Emek Yizrael (IL). **FRIDMAN-DROR, Anna**; 1923900 Kibbutz Dalia (IL). **MANDEL, Ilana**; 2018400 Manof (IL). **BEN-MOSHE, Tehila**; 16 Amzaleg Street,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY

Figure 19



(57) Abstract: Agents comprising at least two moieties separated by a linker, wherein a first moiety binds mCD28 on a surface of a cell and inhibits proteolytic cleavage of the mCD28 and wherein a second moiety increases stability of the first moiety are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))